The inquiry, led by attorney Juan Monteverde, focuses on the fairness of the transaction terms for current Sanara MedTech (NASDAQ: SMTI) stockholders. Monteverde & Associates, a firm recognized in the 2025 ISS Securities Class Action Services Report, is currently inviting shareholders to review the acquisition details for potential legal concerns.
In section Releases
Monteverde & Associates Launches Inquiry Into Sanara MedTech Sale
Sanara MedTech shareholders face a proposed acquisition by MiMedx Group, prompting a formal investigation by New York-based Monteverde & Associates PC. The firm is scrutinizing whether the deal terms—set at $33.00 in cash plus 0.4735 shares of MiMedx stock per share—adequately protect investor interests.
Investors who hold common stock in Sanara MedTech are encouraged to reach out to the firm for a free consultation regarding their rights in this merger. Those seeking additional information can contact Juan Monteverde via email at jmonteverde@monteverdelaw.com or by calling (212) 971-1341. The firm, operating out of the Empire State Building, specializes in securities litigation and maintains a track record of handling cases through trial and appellate courts.
Comments (0)
No comments yet. Be the first!